Interim results from an ongoing phase 2a clinical study of PolyActiva’s PA5108 biodegradable ocular implant in subjects with mild to moderate glaucoma showed a >20% reduction in IOP at 12 and 26 weeks, according to a company news release. The implant is designed to biodegrade after delivering 6 months of latanoprost, allowing for repeat dosing.

A low-dose cohort (n=10), a mid-dose cohort (n=10), and a repeat-dose cohort (n=17) were recruited. A separate group of 8 patients received a second implant at 21 weeks, giving them ongoing, uninterrupted therapy. No product-related adverse effects have been observed.

"For ocular implants to ultimately replace daily eye drops for the treatment of glaucoma, they need to be suitable for repeat administration, which has been a principal goal of PolyActiva's development program," said PolyActiva CEO Vanessa Waddell in a news release. "Our phase 2a results indicate we are well placed to meet that objective."